Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11th at 3:30 p.m. ET. In addition, management will be available for one-on-one meetings with investors.
A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
VP, Investor Relations & Corp. Communications
Direct: (650) 273-4999
Investor and Media Contact:
Stern Investor Relations